MorphoSys AG (MOR)
17.89
+0.02
(+0.11%)
USD |
NASDAQ |
May 03, 16:00
17.90
+0.01
(+0.06%)
After-Hours: 20:00
MorphoSys Enterprise Value: 2.633B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 2.633B |
May 02, 2024 | 2.630B |
May 01, 2024 | 2.576B |
April 30, 2024 | 2.561B |
April 29, 2024 | 2.554B |
April 26, 2024 | 2.656B |
April 25, 2024 | 2.670B |
April 24, 2024 | 2.658B |
April 23, 2024 | 2.656B |
April 22, 2024 | 2.644B |
April 19, 2024 | 2.647B |
April 18, 2024 | 2.658B |
April 17, 2024 | 2.648B |
April 16, 2024 | 2.634B |
April 15, 2024 | 2.645B |
April 12, 2024 | 2.651B |
April 11, 2024 | 2.649B |
April 10, 2024 | 2.645B |
April 09, 2024 | 2.666B |
April 08, 2024 | 2.664B |
April 05, 2024 | 2.655B |
April 04, 2024 | 2.654B |
April 03, 2024 | 2.657B |
April 02, 2024 | 2.651B |
April 01, 2024 | 2.658B |
Date | Value |
---|---|
March 28, 2024 | 2.663B |
March 27, 2024 | 2.663B |
March 26, 2024 | 2.669B |
March 25, 2024 | 2.664B |
March 22, 2024 | 2.669B |
March 21, 2024 | 2.646B |
March 20, 2024 | 2.646B |
March 19, 2024 | 2.655B |
March 18, 2024 | 2.657B |
March 15, 2024 | 2.618B |
March 14, 2024 | 2.633B |
March 13, 2024 | 2.648B |
March 12, 2024 | 2.667B |
March 11, 2024 | 2.625B |
March 08, 2024 | 2.628B |
March 07, 2024 | 2.619B |
March 06, 2024 | 2.612B |
March 05, 2024 | 2.595B |
March 04, 2024 | 2.603B |
March 01, 2024 | 2.597B |
February 29, 2024 | 2.582B |
February 28, 2024 | 2.579B |
February 27, 2024 | 2.592B |
February 26, 2024 | 2.595B |
February 23, 2024 | 2.585B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-62.20M
Minimum
Apr 03 2023
4.437B
Maximum
Jan 09 2020
1.585B
Average
1.377B
Median
Jan 24 2024
Enterprise Value Benchmarks
Incyte Corp | 8.221B |
Novartis AG | 214.39B |
Immatics NV | 638.37M |
Affimed NV | 15.38M |
InflaRx NV | -18.53M |
Enterprise Value Related Metrics
Net Income (Quarterly) | 51.98M |
Revenue (Quarterly) | 63.62M |
Total Expenses (Quarterly) | 151.13M |
EPS Diluted (Quarterly) | 0.3877 |
Gross Profit Margin (Quarterly) | 75.20% |
Profit Margin (Quarterly) | 81.70% |
Earnings Yield | -8.40% |
Normalized Earnings Yield | -9.403 |